Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wyeth is now a wholly owned subsidiary of Pfizer
Patients completing study 3151A4-327 have the opportunity to be treated with DVS SR during the 6 month extension study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Outpatients who have completed double-blind treatment in study 3151A4-327 for fibromyalgia Syndrome with no major protocol violations and no events that would preclude the patient's entry into the long-term open-label study.
Women of childbearing potential must have a negative serum pregnancy test result at study start.
You may not be if
Presence of any new/and or clinically important medical condition that might compromise patient's safety.
Use of prohibited treatment.
Clareo Health | Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome
